ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara achieved record EBITDA/PAT despite significant geopolitical headwinds in West Asia impacting raw material costs.
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹381.6 Cr (+19.6% YoY) and net profit of ₹16.3 Cr (+55.2% YoY) for Q1 FY27.
Solara delivered its highest Q4 revenue in 8 quarters at INR 392cr, driven by a strong base business with 54% gross margins, despite persistent headwinds and negative EBITDA in the Ibuprofen segment.
Solara's base business shows strong momentum, hitting eight-quarter highs in revenue and EBITDA, yet the Ibuprofen segment remains a significant drag, forcing a strategic review and potential divestment of the vertical.
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹387.3 Cr (+41.9% YoY) and net profit of ₹9.6 Cr for Q4 FY26.